Syndax Pharmaceuticals, Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Syndax Pharmaceuticals, Inc. operates as a commercial-stage biopharmaceutical firm dedicated to developing advanced cancer treatments. The company’s portfolio features two key therapeutic candidates that have received FDA approval. Revuforj (revumenib), a selective menin inhibitor, is cleared for relapsed or refractory acute leukemias with KMT2A rearrangements and NPM1 mutations. Concurrently, Niktimvo (axatilimab), a monoclonal antibody that targets the CSF-1 receptor, is approved for treating chronic graft-versus-host disease in patients who have not responded to at least two prior systemic therapies. Both primary compounds are undergoing further clinical investigation for potential expansion into earlier treatment lines, combination regimens, and additional indications such as idiopathic pulmonary fibrosis. Syndax is also advancing Entinostat, a Class 1 HDAC inhibitor, in studies for various solid tumors and specific hematological malignancies. The company maintains strategic alliances, including a global collaboration with Incyte for axatilimab's development and commercialization, alongside other research partnerships. Incorporated in 2005, Syndax Pharmaceuticals is headquartered in Waltham, Massachusetts, concentrating on pioneering therapies to fulfill critical unmet medical requirements.
Company News
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
SNDX Investors with $100,000 in Losses Have Opportunity to Join Syndax Pharmaceuticals, Inc. Fraud Investigation with SBS Law
Syndax's Revuforj® (revumenib) Named to TIME's Best Inventions of 2026 List
Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary Goal
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
Syndax Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Syndax (SNDX)
Syndax Pharmaceuticals Suffers Pipeline Blow
Syndax Pharmaceuticals, BioNTech, Seagate And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Syndax Announces Topline Results from MAXPIRe Phase 2 Trial of Axatilimab in Idiopathic Pulmonary Fibrosis
Cartesian Therapeutics (NASDAQ:RNAC) versus Syndax Pharmaceuticals (NASDAQ:SNDX) Critical Comparison
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax: 'Strong Buy' Revuforj Pipeline Growth And Niktimvo Q4 2026 Data Releases
Syndax Pharmaceuticals: Buy The Pullback Ahead Of Q4 Readouts
Syndax Pharmaceuticals, Inc. (SNDX) Presents at Citigroup's Biopharma Back to School Summit 2026 Transcript
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Announces Participation in September Investor Conferences
BlackRock Inc. Makes New Investment in Syndax Pharmaceuticals, Inc. $SNDX
Citi sees up to 410% upside in 2 biotech stocks: is the risk worth it?
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals, Inc. (SNDX) Q2 2026 Earnings Call Transcript